3.7 Pulmonary Hypertension and Sarcoidosis
Key Takeaways
Suspect pulmonary hypertension from symptoms and risk, use echocardiography to estimate probability, and confirm the relevant haemodynamics with specialist assessment.
Evaluate persistent unexplained breathlessness after pulmonary embolism for chronic thromboembolic disease. Pulmonary hypertension treatment depends on its cause.
Assess suspected sarcoidosis for compatible findings and alternatives, and assess organ involvement before choosing observation or treatment.
Recognise and investigate pulmonary hypertension
Consider pulmonary hypertension (PH) in unexplained exercise limitation, breathlessness, presyncope or syncope. Oedema, a raised jugular venous pressure or a loud pulmonary component of the second heart sound can support suspicion. Review left heart disease, chronic lung disease, prior venous thromboembolism, connective tissue disease and other risk factors. Rapid deterioration, syncope with little exertion or signs of right heart failure warrant urgent specialist assessment. Acute physiological compromise needs emergency care.
Echocardiography estimates the probability of PH and can identify right heart strain or a left heart cause. Right heart catheterisation measures haemodynamics and confirms PH when indicated. Consider pulmonary function, lung imaging and other tests according to the differential. The Mater Hospital hosts the Irish National Pulmonary Hypertension Unit. A patient with persistent unexplained breathlessness after adequate treatment for pulmonary embolism should be assessed for chronic thromboembolic disease. Ventilation/perfusion imaging is an important test for this cause. New acute symptoms need assessment for recurrent pulmonary embolism or another acute problem.
| Haemodynamic pattern at rest | Criteria |
|---|---|
| Pulmonary hypertension | Mean pulmonary arterial pressure (mPAP) greater than 20 mmHg |
| Pre-capillary | mPAP greater than 20 mmHg, pulmonary arterial wedge pressure (PAWP) at most 15 mmHg and pulmonary vascular resistance (PVR) greater than 2 Wood units |
| Isolated post-capillary | mPAP greater than 20 mmHg, PAWP greater than 15 mmHg and PVR at most 2 Wood units |
| Combined post- and pre-capillary | mPAP greater than 20 mmHg, PAWP greater than 15 mmHg and PVR greater than 2 Wood units |
Calculate PVR as (mPAP minus PAWP) divided by cardiac output in L/min. For example, mPAP 32 mmHg, PAWP 12 mmHg and output 4 L/min yield 5 Wood units, which fulfils the pre-capillary criteria. The mechanism still needs to be identified. Pulmonary arterial hypertension (PAH), pulmonary hypertension due to lung disease and chronic thromboembolic pulmonary hypertension can all show this haemodynamic pattern. Left heart disease commonly contributes to post-capillary PH. Treatment of PAH differs from treatment of PH due to left heart or lung disease. Do not start a PAH-targeted medicine solely because pulmonary pressures are elevated. Specialist assessment for chronic thromboembolic pulmonary hypertension includes whether pulmonary endarterectomy, balloon pulmonary angioplasty or medical treatment is appropriate.
Worked follow-up. A patient remains more breathless than before their pulmonary embolism after three months of therapeutic anticoagulation. Review symptoms, other causes and the initial imaging. A mismatched perfusion defect should prompt specialist assessment for chronic thromboembolic disease. The guideline allows investigation earlier in unstable or rapidly deteriorating patients. A negative CT pulmonary angiogram alone can miss distal chronic disease.
ESC/ERS PH guideline · Seventh World Symposium definition and diagnosis · Mater respiratory and PH service.
An adult with persistent breathlessness has an mPAP of 31 mmHg, PAWP of 11 mmHg and cardiac output of 4 L/min at right heart catheterisation. What does this establish?
Isolated post-capillary pulmonary hypertension because the wedge pressure is above 15 mmHg
Pre-capillary pulmonary hypertension, with PVR of 5 Wood units. The underlying cause still needs evaluation
There is no pulmonary hypertension because the mPAP is less than 35 mmHg
PAH is confirmed and chronic thromboembolism and lung disease need no further assessment
Recognise sarcoidosis and assess organs at risk
Sarcoidosis can present with cough, breathlessness, bilateral hilar lymphadenopathy, skin lesions, ankle inflammation or eye symptoms. Löfgren syndrome combines bilateral hilar lymphadenopathy with erythema nodosum and/or periarticular arthritis. Reconsider infection, including tuberculosis when exposure or other findings suggest it, malignancy, and relevant occupational exposure. A diagnosis typically uses a compatible presentation, non-necrotising granulomatous inflammation when tissue is needed, and exclusion of credible alternatives. Granulomas can occur in other diseases. When mediastinal or hilar tissue is needed, the ATS guideline generally favours endobronchial ultrasound-guided sampling as the initial method. A very characteristic presentation can sometimes be followed without lymph node sampling if specialist assessment finds this appropriate and follow-up is reliable.
Assess respiratory symptoms, imaging and lung function. Ask about eye symptoms, palpitations, syncope and neurological symptoms. The ATS recommends baseline calcium and suggests a baseline ECG, eye examination and selected other tests even without symptoms. New syncope, conduction changes or suspected cardiac disease warrant prompt specialist evaluation. Eye pain, photophobia or impaired vision can indicate uveitis and need appropriate urgent review. In a stable patient with mild disease, observation and planned follow-up may be appropriate. The ERS bases systemic treatment on organ risk and symptom burden. Glucocorticoids can be used for patients with pulmonary disease carrying a higher risk of serious progression, with specialist assessment of response and adverse effects. Before immunosuppression, assess credible infectious alternatives and involve the appropriate team.
ATS sarcoidosis diagnostic guideline · ERS sarcoidosis treatment guideline.
An adult with suspected sarcoidosis has enlarging mediastinal and hilar nodes and atypical clinical features. The respiratory team decides that nodal tissue is needed to investigate alternatives including tuberculosis and malignancy. What is the preferred initial nodal sampling approach in the ATS guideline?
Give systemic glucocorticoids before seeking a diagnosis in every patient
Use serum calcium alone to establish the diagnosis
Use a screening chest radiograph in place of tissue
Arrange endobronchial ultrasound-guided lymph node sampling
Sections you finish are checked off in the contents.